Latest News

Ceapro Featured at the 12th International Congress on Engineering and Food (ICEF12) – Gilles Gagnon, M.Sc., MBA, Ceapro’s President and CEO, Honorary Guest VIP Speaker at the ICEF opening ceremony – Bernhard Seifried, Ph.D., Senior Research Scientist and co-inventor of Ceapro’s PGX Technology to present on June 17, 2015

EDMONTON, ALBERTA – June 15, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced its featured participation in the 12th International Congress on Engineering and Food (ICEF12)

Read more

Ceapro Announces Election of Directors at 2015 Shareholders’ Meeting

EDMONTON, ALBERTA – June 9, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William

Read more

Ceapro Inc. Reports First Quarter 2015 Financial and Operations Results

EDMONTON, ALBERTA – June 1, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-months ended March 31, 2015 and provided

Read more

Ceapro to Develop Enabling Pressurized Gas Expanded Technology (PGX) at Commercial and Demonstration Scale – Scale-up of unique, patented PGX enabling technology expected to generate numerous novel bio-based products with improved purity and functionality in several industrial applications

EDMONTON, ALBERTA – May 28, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the healthcare and cosmetic industries, announced today it will embark on a scale-up of its proprietary PGX technology

Read more

Ceapro Announces Appointment of New Chief Financial Officer

EDMONTON, ALBERTA – May 5, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed Stacy Prefontaine, CA, as Chief Financial Officer. Ms. Prefontaine

Read more

Ceapro Appoints Seasoned Pharmaceutical Industry Executive, Ulrich Kosciessa, Ph.D., to its Board of Directors

EDMONTON, ALBERTA – April 28, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its

Read more

Ceapro Reports Record Full-Year 2014 Financial Results – Company posts best full-year financial performance in its history – FY 2014 Revenues increased 36% vs. 2013 – FY 2014 Net Profit increased 806% vs. 2013

EDMONTON, ALBERTA – April 22, 2014 – Ceapro Inc. (TSX-V: CZO) (Ceapro or the Company), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the twelve-months ended December 31, 2014 and provided

Read more

Ceapro Expands License Agreement with University of Alberta for PGX Technology – Worldwide rights granted to Ceapro to develop and commercialize PGX Technology in “All Industrial Fields”

EDMONTON, ALBERTA – February 11, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development

Read more

Ceapro Raises an Additional $310,000 through a Non-Brokered Private Placement

EDMONTON, ALBERTA – February 4, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced

Read more

Ceapro Raises $650,000 through a Non-Brokered Private Placement

EDMONTON, ALBERTA – January 21, 2014 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has received conditional TSX-V approval for and has closed a

Read more
Page 4 of 10« First...23456...10...Last »